Type 1 diabetes: the complete journey
Trace autoimmune beta-cell injury from a silent immune process to insulin deficiency, clinical diagnosis, treatment, and emerging disease modification.
By The Diabetes Guide editorial project · Updated 30 Sept 2026
On this page
Type 1 diabetes is usually an autoimmune condition. The body’s defence system harms the beta cells, so less and less insulin is made.
Step 1: The defenders make a mistake
Genes and something in the environment can lead the immune system to attack beta cells. There is no single proven trigger.
For example: Guards at a school mistake the cooks for strangers.
Step 2: A quiet start
For months or years, remaining cells cover the need, so a person can look healthy while tests show the process has begun.
For example: A leaky roof can hold for weeks before a drip shows in the room.
Step 3: When insulin runs very low
Blood sugar climbs and the body starts making ketones from fat. Too many ketones can cause DKA, which is an emergency.
For example: A car running on an emergency spare tire can go a short way but will soon fail.
Remember: Type 1 is not caused by eating sweets, and insulin must not be stopped.
The full story
Want more? Below is the detailed version with the real science words. It is fine to skip it.
What happens inside the body?
Genetic susceptibility affects immune regulation, but genes are not destiny. Environmental influences are being investigated; there is no single proven trigger that explains every case. T cells, immune cells that recognize molecular targets, participate in beta-cell injury. Autoantibodies are measurable antibodies against the body's own molecules; they help mark the autoimmune process but are not a simple measure of how many cells remain. 1
The stages before diagnosis
Type 1: from susceptibility to clinical disease
Susceptibility. Inherited immune-related variants can increase risk but do not determine destiny.
Read every step in a list
- Susceptibility. Inherited immune-related variants can increase risk but do not determine destiny.
- Autoimmunity. The immune response targets islet antigens. One antibody requires confirmation and follow-up.
- Stage 1. Multiple confirmed islet autoantibodies with normal glucose.
- Stage 2. Multiple autoantibodies with dysglycemia below overt diabetes criteria.
- Stage 3. Clinical diabetes criteria are met; prompt care and insulin management are required.
Stage 1 combines multiple confirmed islet autoantibodies with normal glucose regulation. Stage 2 adds dysglycemia, meaning abnormal glucose that does not yet meet overt diabetes criteria. Stage 3 meets diabetes criteria and may be detected before symptoms, or present with thirst, urination, weight loss or ketoacidosis. Avoid equating Stage 3 exclusively with symptomatic disease. 1
Why someone can look healthy
Remaining beta cells can initially supply enough insulin. A person can therefore have immune markers while glucose and daily functioning appear normal. Progression varies with age, antibody profile and metabolic findings. It can take months or years; a diagram cannot assign a personal deadline.
Biomarkers tell different stories
| Marker | What it tells us | Important limitation |
|---|---|---|
| GAD65, IA-2, ZnT8 antibodies | Evidence of an islet-directed autoimmune response | Results need confirmation and context |
| IAA: insulin autoantibodies | Autoimmunity to insulin, particularly relevant before treatment | Insulin treatment can complicate interpretation |
| C-peptide | The body's own insulin secretion | Depends on glucose stimulation and kidney clearance |
| HbA1c or plasma glucose | Current or recent glucose regulation | Does not alone identify diabetes type |
From insulin deficiency to DKA
When insulin becomes severely insufficient, liver glucose production and fat breakdown are inadequately restrained. Fatty acids reach the liver, which produces ketones. Excess ketones make the blood acidic; glucose-driven urination causes dehydration and electrolyte loss. DKA is the combination of ketosis, acidosis and the relevant metabolic context, not simply a high glucose number. It can occur with only modest glucose elevation, including with some medications. 3
Treatment and disease modification
Insulin replacement, education, glucose monitoring, and prevention of hypoglycemia form the core of care. Automated insulin delivery can reduce management burden, but still requires supplies, training and a backup plan. Never stop insulin because a research therapy sounds promising. 4
Teplizumab modifies immune activity in selected people. Its US indications changed during 2026; the current label distinguishes delaying Stage 3 in eligible Stage 2 patients from preserving secretion in selected recently diagnosed children. Neither indication means a universal cure. 5
The open research problem
Preserving cells, replacing cells and protecting cells are separate engineering tasks. A replacement graft can face donor rejection and the original autoimmune process. Explore the research pipeline and stem-cell-derived islets.
Trace the evidence
Sources and further reading
1.Staging Presymptomatic Type 1 Diabetes: Scientific Statement (opens in a new tab)
Insel et al.; JDRF, Endocrine Society, ADA · 2015 · Guideline
Who was studied, limits and source check
Limitations: Foundational staging; rates vary by age and antibody profile. Use updated guidelines for monitoring.
Source checked 2026-09-30. See the original publication for full methods.
2.Symptoms & Causes of Diabetes (opens in a new tab)
NIH / NIDDK · 2026 · Reference
Who was studied, limits and source check
Limitations: Access year shown. Symptoms overlap with many conditions and cannot establish diabetes type.
Source checked 2026-09-30. See the original publication for full methods.
3.Diabetic Ketoacidosis (opens in a new tab)
US Centers for Disease Control and Prevention · 2024 · Reference
Who was studied, limits and source check
Limitations: General patient education, not a substitute for emergency assessment.
Source checked 2026-09-30. See the original publication for full methods.
4.Pharmacologic Approaches to Glycemic Treatment: Standards of Care 2026 (opens in a new tab)
American Diabetes Association · 2026 · Guideline
Who was studied, limits and source check
Limitations: Recommendations require shared clinical decisions; benefits and contraindications vary by drug.
Source checked 2026-09-30. See the original publication for full methods.
5.Tzield prescribing information, revised June 2026 (opens in a new tab)
US Food and Drug Administration · 2026 · Regulatory
Who was studied, limits and source check
Limitations: US label. Age and staging criteria differ between indications; specialist evaluation and infection precautions are required.
Source checked 2026-09-30. See the original publication for full methods.
Source checking is an editorial literature check, not independent medical review. This page is for learning. It cannot diagnose you or make a treatment plan. Evidence labels describe the cited claims, not the whole topic.
What does “Established” mean?
Doctors and scientists agree. This is well known. Like “the sun rises in the east”.
Keep reading
The body
The one-page mental model
Diabetes means there is too much sugar in the blood for too long, because the body does not have enough insulin or cannot use it well.
Type 2
Type 2 diabetes: how the system changes
Type 2 diabetes happens when the body’s need for insulin grows and the pancreas cannot keep up, so sugar slowly rises.
Detection
Detecting diabetes early
Finding diabetes early means asking four different questions: who is at risk, who might have it now, does a test confirm it, and which type is it.